<DOC>
	<DOCNO>NCT00224497</DOCNO>
	<brief_summary>The purpose study find SB-742457 safe treatment effect symptoms mild moderate Alzheimer 's disease . SB-742457 new treatment thought increase level certain chemical brain often decrease patient Alzheimer 's disease .</brief_summary>
	<brief_title>A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis probable mildtomoderate Alzheimer 's disease determine NINCDSADRDA DSMIV criterion MMSE score 1224 . Subjects caregiver must provide informed consent prior study entry . Adequate blood pressure laboratory value . Exclusion criterion : Females childbearing potential . Have cause dementia vascular damage , depression , bipolar affective disorder , schizophrenia , syphilis , vitamin B12 deficiency thyroid deficiency . Subjects take medication Alzheimer 's disease centrally act agent might impact study outcome . Subjects take agent theoretical risk interaction SB742457 . Subjects know hypersensitivity sunlight seizure .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>cognition global functioning</keyword>
	<keyword>symptomatic</keyword>
	<keyword>B-742457</keyword>
</DOC>